Regorafenib：轉移性大腸直腸癌與胃腸道基質瘤之口服標靶藥物

針對腫瘤細胞特異性的標靶治療，能夠抑制腫瘤生長及擴散，不僅具有良好的抗癌效果，也能減少對於正常細胞的傷害，已然成為目前癌症治療的趨勢。Regorafenib是一個口服小分子多重標靶藥物，臨床上應用於治療轉移性大腸直腸癌及胃腸道基質瘤。作為其他藥物治療下發生疾病惡化或無法耐受時的後線藥物，regorafenib能顯著改善轉移性大腸直腸癌病人的整體存活時間及無疾病惡化時間，用於胃腸道基質瘤亦能有效增加無疾病惡化時間。針對亞洲人進行的試驗則發現亞洲人發生手足皮膚反應及肝臟不良反應的機會較高。成本效果的數據分析顯示regorafenib用於轉移性大腸直腸癌僅增加少許的益處但卻需付出很高的成本，而用於胃腸道基質瘤則符合成本效果。

關鍵字

轉移性大腸直腸癌；胃腸道基質瘤；成本效果分析

並列摘要

Specifically targeting cancer cell biology, targeted therapy provides antitumor activity with limited harm to normal tissues. Targeted therapy has become a pivotal therapy for various malignancies. Regorafenib, an oral small-molecule multi-targeted kinase inhibitor, has been approved as late line therapy for metastatic colorectal cancer and gastrointestinal stromal tumors. In phase 3 clinical trials, regorafenib has been shown to significantly prolong overall and progression-free survival for patients with metastatic colorectal cancer and prolong progression-free survival for patients with metastatic GIST. Asian patients have higher rates of hand-foot skin reaction and hepatic adverse reactions. Cost-effectiveness analyses showed that regorafenib provides limited benefits with high costs for metastatic colorectal cancer, but is a cost-effective treatment for GIST.

並列關鍵字

regorafenib ； metastatic colorectal cancer ； GIST ； cost-effectiveness analysis

參考文獻

Sawyers C: Targeted cancer therapy. Nature 2004;432:294-7."

Wilhelm SM, Dumas J, Adnane L, et al: Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011;129:245-55."

Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-12."

Li J, Qin S, Xu R, et al: Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015;16:619-29."

NCCN Clinical Practice Guidelines in Oncology. Soft Tissue Sarcoma (version 1.2015)."

延伸閱讀

陳昭姿（2013）。Regorafenib－治療轉移性大腸直腸癌的最新接力棒。當代醫學，(476)，425-427。https://doi.org/10.29941/MT.201306_(476).0005
黃瀅璇（2016）。轉移性大腸直腸癌新藥－Regorafenib (Stivarga®癌瑞格)。彰基藥訊，24(1)，1-3。https://www.airitilibrary.com/Article/Detail?DocID=P20140725001-201603-201606230020-201606230020-1-3
Hsieh, C. H., Hsu, T. C., Chen, Y. J., Hsu, H. H., Liu, C. K., Hung, S. K., Lai, Y. L., Chen, H. W., & Chang, K. H. (2006). 局部晚期直腸癌手術後放射治療併用Uracil-Tegafur及Leucovorin之療效初探. 放射治療與腫瘤學, 13(2), 117-125. https://doi.org/10.6316/TRO/200613(2)117
Chang, T. C., Liang, J. T., Lin, B. R., & Huang, J. (2009). Oncological Results for the Surgical Treatment of Rectal Gastrointestinal Stromal Tumor. 中華民國大腸直腸外科醫學會雜誌, 20(4), 87-93. https://doi.org/10.6312/SCRSTW.2009.20(4).09811
Yang, H. L., Chang, S. C., Lan, Y. T., Wang, H. S., Yang, S. H., Jiang, J. K., Chen, W. S., Lin, T. C., & Lin, J. K. (2011). The Clinicopathologic Features and Outcome of Patients with Gastrointestinal Stromal Tumors in Colorectal Region. 中華民國大腸直腸外科醫學會雜誌, 22(4), 115-121. https://doi.org/10.6312/SCRSTW.2011.22(4).10005

國際替代計量

Regorafenib：轉移性大腸直腸癌與胃腸道基質瘤之口服標靶藥物

全文下載

主題瀏覽